Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1959 1
1961 1
1962 7
1963 7
1964 3
1965 2
1966 4
1967 7
1968 4
1969 2
1970 6
1971 5
1972 10
1973 3
1974 7
1975 8
1976 5
1977 3
1978 3
1979 6
1980 5
1981 3
1982 6
1983 5
1984 6
1985 8
1986 13
1987 11
1988 13
1989 8
1990 11
1991 13
1992 18
1993 23
1994 16
1995 16
1996 14
1997 16
1998 23
1999 22
2000 46
2001 47
2002 49
2003 57
2004 74
2005 93
2006 105
2007 163
2008 154
2009 192
2010 227
2011 242
2012 243
2013 229
2014 247
2015 291
2016 293
2017 282
2018 292
2019 300
2020 369
2021 462
2022 492
2023 421
2024 455
2025 311

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,786 results

Results by year

Filters applied: . Clear all
Page 1
Inflammation in Wound Healing and Pathological Scarring.
Hong YK, Chang YH, Lin YC, Chen B, Guevara BEK, Hsu CK. Hong YK, et al. Among authors: lin yc. Adv Wound Care (New Rochelle). 2023 May;12(5):288-300. doi: 10.1089/wound.2021.0161. Adv Wound Care (New Rochelle). 2023. PMID: 36541356 Review.
Toddler's Fracture.
Lin CH, Lin YC. Lin CH, et al. Among authors: lin yc. N Engl J Med. 2023 Dec 7;389(23):e50. doi: 10.1056/NEJMicm2304910. Epub 2023 Dec 2. N Engl J Med. 2023. PMID: 38051812 No abstract available.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
Gorelik M, Chung SA, Ardalan K, Binstadt BA, Friedman K, Hayward K, Imundo LF, Lapidus SK, Kim S, Son MB, Sule S, Tremoulet AH, Van Mater H, Yildirim-Toruner C, Langford CA, Maz M, Abril A, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Merkel PA, Rhee RL, Seo P, Stone JH, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot M, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. Gorelik M, et al. Among authors: lin yc. Arthritis Rheumatol. 2022 Apr;74(4):586-596. doi: 10.1002/art.42041. Epub 2022 Mar 7. Arthritis Rheumatol. 2022. PMID: 35257501 Free PMC article.
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.
Yao H, Yan M, Tong Z, Wu X, Ryu MH, Park JJ, Kim JH, Zhong Y, Zhao Y, Voskoboynik M, Yin Y, Liu K, Kaubisch A, Liu C, Zhang J, Wang S, Im SA, Ganju V, Barve M, Li H, Ye C, Roy AC, Bai LY, Yen CJ, Gu S, Lin YC, Wu L, Bao L, Zhao K, Shen Y, Rong S, Zhu X, Song E. Yao H, et al. Among authors: lin yc. J Clin Oncol. 2024 Oct 10;42(29):3453-3465. doi: 10.1200/JCO.23.02044. Epub 2024 Jun 20. J Clin Oncol. 2024. PMID: 38900984 Clinical Trial.
Vaccination induces broadly neutralizing antibody precursors to HIV gp41.
Schiffner T, Phung I, Ray R, Irimia A, Tian M, Swanson O, Lee JH, Lee CD, Marina-Zárate E, Cho SY, Huang J, Ozorowski G, Skog PD, Serra AM, Rantalainen K, Allen JD, Baboo S, Rodriguez OL, Himansu S, Zhou J, Hurtado J, Flynn CT, McKenney K, Havenar-Daughton C, Saha S, Shields K, Schultze S, Smith ML, Liang CH, Toy L, Pecetta S, Lin YC, Willis JR, Sesterhenn F, Kulp DW, Hu X, Cottrell CA, Zhou X, Ruiz J, Wang X, Nair U, Kirsch KH, Cheng HL, Davis J, Kalyuzhniy O, Liguori A, Diedrich JK, Ngo JT, Lewis V, Phelps N, Tingle RD, Spencer S, Georgeson E, Adachi Y, Kubitz M, Eskandarzadeh S, Elsliger MA, Amara RR, Landais E, Briney B, Burton DR, Carnathan DG, Silvestri G, Watson CT, Yates JR 3rd, Paulson JC, Crispin M, Grigoryan G, Ward AB, Sok D, Alt FW, Wilson IA, Batista FD, Crotty S, Schief WR. Schiffner T, et al. Among authors: lin yc. Nat Immunol. 2024 Jun;25(6):1073-1082. doi: 10.1038/s41590-024-01833-w. Epub 2024 May 30. Nat Immunol. 2024. PMID: 38816615 Free PMC article.
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, Şendur MAN, Czyżewicz G, Caro RB, Lee KH, Johnson ML, Karadurmuş N, Grohé C, Baka S, Csőszi T, Ahn JS, Califano R, Yang TY, Kemal Y, Ballinger M, Cuchelkar V, Graupner V, Lin YC, Chakrabarti D, Bhatt K, Cai G, Iannone R, Reck M; IMforte investigators. Paz-Ares L, et al. Among authors: lin yc. Lancet. 2025 Jun 14;405(10495):2129-2143. doi: 10.1016/S0140-6736(25)01011-6. Epub 2025 Jun 2. Lancet. 2025. PMID: 40473449 Clinical Trial.
5,786 results